Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Myelofibrosis (MF) Market Expected To Grow In Terms Of Size?

The market for myelofibrosis (mf) has seen consistent growth in recent years, expanding from $1.5 billion in 2024 to $1.55 billion in 2025, with a compound annual growth rate (CAGR) of 3.2%. The historical growth of this market can be credited to factors such as the rising occurrence of myeloproliferative neoplasms, increasing awareness leading to earlier diagnoses, a surge in the usage of JAK inhibitors, improved access to bone marrow transplants, and a boost in regulatory approvals for innovative treatments.

The market size for myelofibrosis (mf) is projected to experience consistent expansion in the forthcoming years, reaching $1.75 billion in 2029 with a compound annual growth rate (CAGR) of 3.1%. The forecast period’s growth is linked to several factors including the increase in demand for tailored treatment methods, a rise in clinical tests for gene and cell therapies, extensive use of combined therapies, expanded healthcare coverage for uncommon diseases, and escalated investment in hematology care. Noteworthy trends for the forecast period encompass advancements in gene-editing technologies, cutting-edge developments in drugs targeting fibrosis, evolution of the next generation of JAK inhibitors, a burgeoning interest in immunotherapy for myelofibrosis, and a wider application of artificial intelligence in drug discovery.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp

What Are The Primary Factors Supporting The Myelofibrosis (MF) Market Expansion?

The anticipated expansion of the myelofibrosis (MF) market is highly attributed to the escalating demand for targeted therapies. These are custom-made healthcare treatments and decisions, designed in accordance with individual genetic, lifestyle and environmental circumstances. Major enhancements in the fields of genomics, biotechnology, and data analytics, triggering demand for these therapies, allow for more exact, effective, and personalized treatments. MF plays an essential role in devising targeted therapies by spotlighting essential molecular channels like the JAK-STAT signaling, this lays the groundwork for creating precision treatments like JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib), essential for managing symptoms and decelerating disease progression. For example, in April 2024, as per the American Society of Gene & Cell Therapy, a US government body, there was a surge in the total number of therapies, with Phase I therapies witnessing a notable escalation of 11%, the most accelerated growth rate since Q4 2022. Hence, the myelofibrosis (MF) market growth is propelled by the escalating demand for targeted therapies.

Which Segmentation Categories Are Highlighted In The Myelofibrosis (MF) Market Analysis?

The myelofibrosis (mf)market covered in this report is segmented –

1) By Drug Type: Jak Inhibitor; Immunomodulators; Hydroxyurea; Other Drug Types

2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Jak Inhibitor: Ruxolitinib; Fedratinib; Momelotinib; Itacitinib

2) By Immunomodulators: Thalidomide; Lenalidomide; Pomalidomide

3) By Hydroxyurea: Oral Hydroxyurea; Injectable Hydroxyurea

4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs); Danazol; Monoclonal Antibodies; Chemotherapy Agents

Which Notable Trends Are Transforming The Myelofibrosis (MF) Market Outlook?

Companies in the myelofibrosis (MF) market are expanding their portfolios with targeted therapies like JAK1/JAK2 and ACVR1 inhibitors to slow disease progression and manage symptoms like anemia. These inhibitors regulate the overactive pathways involved in MF development. In September 2023, UK-based GSK plc received FDA approval for Ojjaara (momelotinib), a dual-action treatment targeting both JAK1/JAK2 and ACVR1. The drug reduces inflammation, improves hemoglobin levels, and lowers the need for blood transfusions, representing a significant advancement for MF patients with anemia.

Which Organizations Are At The Forefront Of The Myelofibrosis (MF) Market?

Major companies operating in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/myelofibrosis-mf-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Myelofibrosis (MF) Market?

North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (MF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21226&type=smp

Browse Through More Reports Similar to the Global Myelofibrosis (MF) Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Bone Marrow Transplantation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-marrow-transplantation-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model